ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0890 • ACR Convergence 2025

    Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways

    Julia Nicole Zeid1, Kaitlyn Arce2, Nanxi Guo1, Kartik Bhamidipati3, Kevin Wei4, Larry Moreland5, Fan Zhang6 and Anna Helena Jonsson2, 1University of Colorado School of Medicine, Aurora, 2University of Colorado School of Medicine, Aurora, CO, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 5University of Colorado, Denver, CO, 6The University of Colorado, Aurora, CO

    Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…
  • Abstract Number: 0561 • ACR Convergence 2025

    Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings

    Alan Kivitz1, Linda Grinnell-Merrick2, Tim Nguyen2, Ariane Faucher3, Riley Taiji3, Francis Vekeman3 and Atul Singhal4, 1Altoona Center for Clinical Research, Duncansville, PA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3STATLOG, Inc, Montreal, QC, Canada, 4SouthWest Arthritis Research Group, Mesquite, TX

    Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…
  • Abstract Number: 0861 • ACR Convergence 2025

    Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies

    Xueting Yuan1, Menghua Cai2, Lu Gao2, Chen Yu3, Jia Shi4, Yinghui Li2, jiuliang Zhao1, Dong Xu5, Chaojun Hu1, Mengtao Li6, Xiaofeng Zeng7, jianmin Zhang2 and Qian Wang6, 1Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), 2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), 3Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), 4University of Washington, Seattle, WA, 5Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), 6Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 7Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)

    Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
  • Abstract Number: 0858 • ACR Convergence 2025

    IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS

    Kavya Sugur1, Chao Liu2, Emily Chong3, Srilakshmi Yalavarthi4, Katarina Kmetova5, Wenying Liang6, Emily Becker6, Gavin Poppei6, Cyrus Sarosh7, NaveenKumar Somanathapura3, Ajay Tambralli3, Jason S. Knight3 and Yu (Ray) Zuo3, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 2University of Michigan, Superior Charter Twp, MI, 3University of Michigan, Ann arbor, MI, 4Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, 5Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 6University of Michigan, Ann arbor, 7University of Michigan, Temperance, MI

    Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in antiphospholipid syndrome (APS), with rates of accelerated atherosclerosis comparable to those seen in…
  • Abstract Number: 0006 • ACR Convergence 2025

    QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis

    Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
  • Abstract Number: 0088 • ACR Convergence 2025

    Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis

    Lyndsey Cole1, Brendan Allen2, Sucai Liu2, Marie Feser3, Le Yi Phyo2, LauraKay Moss2, Daniel Frank2, J. Kirk Harris2, Kristen Demoruelle4, Kevin Deane5, V. Michael Holers6 and Kristine Kuhn7, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 6University of Colorado Anschutz Medical Campus, Aurora, 72022 - 2023 / Adult/ University of Colorado, Aurora, CO

    Background/Purpose: The mucosal origins hypothesis of RA proposes that immune responses to microorganisms at mucosal sites (e.g. intestine) lead to systemic inflammation and autoimmunity. Little…
  • Abstract Number: 0094 • ACR Convergence 2025

    Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs

    Sagrario Corrales1, Laura muñoz-Barrera1, Rafaela Ortega-Castro2, Elena Moreno-Caño3, Jerusalén Calvo4, Concepción Aranda-Valera4, Lourdes Ladehesa5, Pilar Font6, Ismael Sanchez-Pareja1, M Carmen Abalos-Aguilera7, Desiree Ruiz-Vilchez8, Christian Merlo9, MARIA ANGELES AGUIRRE ZAMORANO1, Tomás Cerdó1, Nuria Barbarroja10, Marta Alarcon-Riquelme11, Alejandro Escudero Contreras4, Carlos Pérez Sánchez12 and Chary López pedrera13, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 3IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 4IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 5IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 7Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 8Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 9Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 11Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 12Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 13Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain

    Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…
  • Abstract Number: 0089 • ACR Convergence 2025

    Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis

    Maria-Eugenia Miranda-Carus1, Mariana Gutierrez-Riart2, Beatriz Nieto-Carvalhal3, Laura Nuño2, Alejandro Villalba1, Diana Peiteado1, Irene Monjo Henry1, Marta Novella-Navarro1 and Eugenio de Miguel1, 1Hospital Universitario La Paz, Madrid, Spain, 2Hospital Universitario La Paz, Madrid, 3Hospital Universitario La Paz, Mdrid

    Background/Purpose: Subjects with clinically suspect arthralgia (CSA) are at risk for developing rheumatoid arthritis (RA) and therapeutic interventions may prevent or delay progression. Still, a…
  • Abstract Number: 0008 • ACR Convergence 2025

    Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform

    Julia Manasson1, Liliana Sanmarco2, Alex Pellerin2, Maria Cecilia Ramello2, Agustin Plasencia2, Jordan Anderson2, Tobias Green2, Andita Newton2, Ryan Peckner2, Yi Xing2, Heather Vital3, Nathan Higginson-Scott2, John Sundy4, Kevin L. Otipoby2 and Ivan Mascanfroni2, 1Seismic Therapeutic, New York, NY, 2Seismic Therapeutic, Watertown, MA, 3Seismic Therapeutic, Lexington, MA, 4Seismic Therapeutic, Durham, NC

    Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
  • Abstract Number: 0084 • ACR Convergence 2025

    Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts

    Keita Okamoto1, Yasuto Araki2, Yoshimi Aizaki2, Hiroshi Kajiyama3, Kazuhiro Yokota2, Yu Funakubo2, Yuho Kadono4, Yuji Akiyama5 and Toshihide Mimura6, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-chou, Iruma-gun, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, 4Department of Orthopaedic Surgery, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, 5Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, 6Saitama Seikeikai Hospital, Higashimatsuyama, Saitama, Japan

    Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASFs) produce various matrix metalloproteinases (MMPs), cytokines, and chemokines. Histone lysine methylation has been shown to play an important role…
  • Abstract Number: 0092 • ACR Convergence 2025

    SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging

    Mojtaba S. Fazli1, Mariani Diaz Deluna2, Suzanne Tamang2 and Robert Fairchild2, 1Stanford University, San Francisco, CA, 2Stanford University, Stanford, CA

    Background/Purpose: Rheumatology musculoskeletal ultrasound (MSKUS) is a powerful technique to identify and differentiate arthritidies joint pathology, yet MSKUS is highly dependent on user experience. Techniques…
  • Abstract Number: 0059 • ACR Convergence 2025

    Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner

    Ryan D. Stultz1, Payton Hermanson2, Noelle Mullin3, Simeon Ramsey3 and Christian Lood2, 1University of Washington, Division of Rheumatology, Seattle, WA, 2University of Washington, Seattle, WA, 3Pfizer Inc., Cambridge, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that disproportionately affects females over males (3:1). Although sex-based immune differences have been documented, particularly…
  • Abstract Number: 0056 • ACR Convergence 2025

    Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model

    Maripat Corr1, Grace Hsueh2, Aaron place2, David Lucas2 and NANCY LANE3, 1ucsd, San Diego, CA, 2ANI Pharmaceuticals, Inc., Baudette, MN, 3University of California at Davis, School of Medicine, Sacramento, CA

    Background/Purpose: Melanocortin receptor agonists, such as adrenocorticotropic hormone (ACTH), are anti-inflammatory with pleotropic functions. We aimed to evaluate the effects of a repository corticotropin injection…
  • Abstract Number: 0082 • ACR Convergence 2025

    IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model

    Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
  • Abstract Number: 0037 • ACR Convergence 2025

    A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors

    Natalie McCormick1, Sharan Rai2, Chio Yokose3, Tony Merriman4, Robert Terkeltaub5 and Hyon K. Choi6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Waltham, MA, 4University of Alabama at Birmingham, Homewood, AL, 5Retired, San Diego, CA, 6MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology